Engaging with healthcare professionals
As a healthcare company, we regularly work with healthcare professionals. From collaborating on clinical trials to providing high quality, balanced information about our medicines and vaccines, in all our interactions we aim to be transparent about our work, operate with integrity, and always put the interests of patients first.
Please see our code on HCP engagement (PDF).
Helping HCPs understand the latest data and clinical use of our medicines and vaccines
For patients to benefit from new medical innovations, HCPs need to access and understand the latest available data and clinical use of the product. Our ability to provide or clarify new data to HCPs is a crucial part of introducing new ideas that have the potential to improve patient health.
Consistent feedback from HCPs has shown that they have a clear preference to learn about new data and clinical experience through peer-to-peer programmes with global expert practitioners who have direct experience with our medicines.
How we engage HCPs to speak about our medicines and vaccines
To help HCPs share new data on our products and understand their clinical use, in some cases we:
- make fair market value payments to global expert practitioners who speak about the new science behind selected GSK products, their associated diseases and clinical practice in promotional settings including national meetings, speaker training meetings, GSK standalone meetings, satellite symposia and webinars.
- pay reasonable travel costs (except in the US) for an HCP to attend a GSK-organised standalone meeting to learn about data and clinical expertise.
- directly pay registration fees for HCPs to attend remote congress webinars/webcasts. We do not sponsor HCPs to attend local and international conferences.
This policy applies for a period of 24 months from marketing authorisation of a new medicine or vaccine, and/or for 12 months following significant new data, as this is the point at which HCPs have the most need to know about data from our products.
Implementation of the policy is limited to select products in certain countries around the world. Implementation in a country is subject to management approval, and is dependent on an assessment of risk in that country.
Applying our values to speaker engagement
Controls and training are in place to support our Global Speaker Programmes Policy, including measures to track appropriate payment and use of external speakers. We also continue to increase the use of digital channels to engage with HCPs and are making further investments in digital platforms and channels with the aim of delivering more personalised support, a better customer experience and a more effective cascade of information to HCPs.
Reporting the payments we make to HCPs
We are committed to disclosing the payments we make to HCPs and intend to expand our reporting of payments to individual HCPs.
Where legally permitted, we will report individual-level payments made each year to HCPs for attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.
For many years, we have sought to show that whenever we talk to a doctor, nurse or other prescriber, it is patients’ interests that always come first. We understand that our role in providing HCPs with new data and information about our medicines, must be done clearly and without any perception of conflict of interest. We believe that transparent scientific dialogue and engagement with experts is in the interests of all those working to develop new medicines, improve clinical practice and care for patients. These are the principles that underpin our policy of engagement with HCPs and we remain fully committed to them.
Find out more
Vaccines travel sponsorship
Support for travel sponsorship for global/international independent medical education activities or scientific congresses
Healthcare professionals (HCPs) help us identify potential volunteers for clinical trials, administer the investigational medicine or vaccine to patients, and monitor the results. This unique medical insight and knowledge is vital to the development of new treatments.
At the core of these relationships is a shared concern for improving the health of patients, based on our values of transparency, respect, integrity and patient focus.
All HCPs who work with us on clinical trials have contracts and are paid for their work on these clinical trials. This payment covers their time, plus the cost of investigations they may need to carry out regarding the suitability of a patient and the effectiveness of the treatment.
We have strict policies governing all our work with HCPs. These state that:
- all clinical trial investigators are selected solely on their qualifications to conduct good quality clinical research
- their history of using or not using GSK products must not be taken into account when deciding whether to include them as clinical trial investigators
- no payments are offered or made to influence their judgement on whether to enrol or maintain a patient in a clinical study
- gifts are not permissible to healthcare professionals involved in research projects for GSK
- all payments to HCPs must be governed by contracts
- any payment must reflect fair market value for the work performed and the services provided.
We also have a commitment to publicly disclose the research payments that are made to healthcare professionals and to their institutions for conducting clinical research.
We acknowledge the importance of increased transparency and of putting the patient at the centre of every decision we take. We are committed to disclosing the payments we make to HCPs.
Where we conduct Global Speaker Programmes and it is legally permitted, we will report individual level payments made each year to HCPs for costs associated with attending educational meetings and for the provision of services, such as speaking at events or attending advisory boards. Where individual level disclosure is not legally permitted, we will continue to report aggregate payments.
Disclosure by region
We were one of the first pharmaceutical companies in the USA to voluntarily disclose information about our work with physicians
We fully support the EFPIA's Code on the disclosure of individual transfers of value from pharmaceutical companies to healthcare professionals and healthcare organisations
Rest of the world
We continue to support and work towards transparency as industry associations or governments establish specific guidelines for disclosure around the world
Our values and expectations are at the heart of everything we do